Gene therapy for advanced retinitis pigmentosa (ZM-02 injection)
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests a new gene therapy injection (ZM-02) that uses light-sensitive proteins to help restore vision in people with advanced retinitis pigmentosa. It’s designed to see if the treatment is safe and can improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 60 years old.
- You have advanced retinitis pigmentosa (RP) – a disease that causes vision loss.
- Your vision in the study eye is very poor, at or below a certain level (like light perception or counting fingers).
- You have enough healthy retina remaining for the gene therapy to work.
- You do not have any other eye conditions or infections that could interfere with the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy injection (UGX202) for people with advanced retinitis pigmentosa (RP) who have very poor vision. It aims to see if the treatment can help improve or preserve sight.
This trial tests a new peptide therapy for people with retinitis pigmentosa (RP), a genetic eye disease that causes vision loss. The goal is to see if the treatment is safe and can help slow or improve vision loss.
This trial tests a gentle laser treatment (SML) for people with retinitis pigmentosa (RP), an inherited eye disease that slowly causes vision loss. The goal is to see if the laser can help slow or improve vision problems like night blindness and tunnel vision.
This experimental gene therapy (ZM-02) is designed for people with advanced retinitis pigmentosa who have very poor vision (counting fingers or worse). It aims to see if the treatment is safe and can improve vision by replacing a faulty gene in the retina.
This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.
This program tests an experimental gene therapy for adults with retinitis pigmentosa (RP), an inherited eye disease that causes vision loss. It aims to see if the treatment can help preserve or improve vision.
Hear when a new Retinitis Pigmentosa (RP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.